A decade since the first wave of mobile device health apps hit the market there remain few designed specifically for patients who are undergoing radiation therapy for cancer. This review offers some useful tools available for patient education, organization, and coping.
Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.
A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.
Results from the phase 3 S-TRAC clinical trial suggested that for selected young and otherwise healthy patients, toxicities of sunitinib are manageable.
The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).
Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).
“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”
There was no benefit observed with the use of rituximab in the maintenance setting in Waldenström macroglobulinemia.
No detectable differences were found in major response rate at 6 months and 12 months between patients with and without CXCR4 mutations.
More than half of the patients with CLL included in the retrospective study first received a novel agent in the second-line setting.
